

Adam M Farkas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5178614/publications.pdf>

Version: 2024-02-01

18
papers

1,691
citations

759233

12
h-index

888059

17
g-index

20
all docs

20
docs citations

20
times ranked

5267
citing authors

#	ARTICLE	IF	CITATIONS
1	Endogenous HMGB1 regulates autophagy. <i>Journal of Cell Biology</i> , 2010, 190, 881-892.	5.2	819
2	The receptor for advanced glycation end products (RAGE) sustains autophagy and limits apoptosis, promoting pancreatic tumor cell survival. <i>Cell Death and Differentiation</i> , 2010, 17, 666-676.	11.2	281
3	Intestinal Monocyte-Derived Macrophages Control Commensal-Specific Th17 Responses. <i>Cell Reports</i> , 2015, 12, 1314-1324.	6.4	119
4	Estrogen Receptor β Functions through Nongenomic Mechanisms in Lung Cancer Cells. <i>Molecular Endocrinology</i> , 2009, 23, 146-156.	3.7	104
5	Fibroblast Growth Factor Receptor 3 Alterations and Response to PD-1/PD-L1 Blockade in Patients with Metastatic Urothelial Cancer. <i>European Urology</i> , 2019, 76, 599-603.	1.9	95
6	Induction of Th17 cells by segmented filamentous bacteria in the murine intestine. <i>Journal of Immunological Methods</i> , 2015, 421, 104-111.	1.4	80
7	Myeloid Cell-associated Resistance to PD-1/PD-L1 Blockade in Urothelial Cancer Revealed Through Bulk and Single-cell RNA Sequencing. <i>Clinical Cancer Research</i> , 2021, 27, 4287-4300.	7.0	42
8	Altered glycosylation of MUC1 influences its association with CIN85: the role of this novel complex in cancer cell invasion and migration. <i>Oncotarget</i> , 2013, 4, 1686-1697.	1.8	37
9	Bacillus Calmette-Guerin (BCG): Its fight against pathogens and cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 121-129.	1.6	29
10	Vaccines based on abnormal self-antigens as tumor-associated antigens: Immune regulation. <i>Seminars in Immunology</i> , 2010, 22, 125-131.	5.6	24
11	Biological activities of cytokine-neutralizing hyaluronic acid-antibody conjugates. <i>Wound Repair and Regeneration</i> , 2010, 18, 302-310.	3.0	16
12	Immune phenotype of peripheral blood mononuclear cells in patients with high-risk non-muscle invasive bladder cancer. <i>World Journal of Urology</i> , 2018, 36, 1741-1748.	2.2	13
13	TIM-3 and TIGIT are possible immune checkpoint targets in patients with bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 403-406.	1.6	9
14	Antigen Choice Determines Vaccine-Induced Generation of Immunogenic versus Tolerogenic Dendritic Cells That Are Marked by Differential Expression of Pancreatic Enzymes. <i>Journal of Immunology</i> , 2013, 190, 3319-3327.	0.8	6
15	Escaping Negative Selection: ILC You in the Gut. <i>Immunity</i> , 2015, 43, 12-14.	14.3	6
16	Harnessing Natural Killer Cell Function for Genitourinary Cancers. <i>Urologic Clinics of North America</i> , 2020, 47, 433-442.	1.8	6
17	Novel Mechanisms Underlying the Immediate and Transient Global Tolerization of Splenic Dendritic Cells after Vaccination with a Self-Antigen. <i>Journal of Immunology</i> , 2014, 192, 658-665.	0.8	3
18	Abstract P046: NKG2A and HLA-E define a novel alternative immune checkpoint axis in bladder cancer. , 2022, , .		0